198 related articles for article (PubMed ID: 26820170)
1. Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells.
Zhang P; Xing Z; Li X; Song Y; Zhao J; Xiao Y; Xing Y
Int J Oncol; 2016 Apr; 48(4):1417-25. PubMed ID: 26820170
[TBL] [Abstract][Full Text] [Related]
2. Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.
Karashima T; Fukuhara H; Tamura K; Ashida S; Kamada M; Inoue K; Taguchi T; Kuroda N; Shuin T
Int J Urol; 2013 Sep; 20(9):923-30. PubMed ID: 23379954
[TBL] [Abstract][Full Text] [Related]
3. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z
Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581
[TBL] [Abstract][Full Text] [Related]
4. Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer.
Yu X; Liu L; Cai B; He Y; Wan X
Cancer Sci; 2008 Mar; 99(3):543-52. PubMed ID: 18201274
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
7. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
8. Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
Liu S; Gao M; Wang X; Ding S; Lv J; Gao D; Wang Z; Niu Z
Oncotarget; 2016 Nov; 7(48):79141-79153. PubMed ID: 27816967
[TBL] [Abstract][Full Text] [Related]
9. Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
Callaghan C; Peralta D; Liu J; Mandava SH; Maddox M; Dash S; Tarr MA; Lee BR
J Pharm Sci; 2016 Jan; 105(1):284-92. PubMed ID: 26852860
[TBL] [Abstract][Full Text] [Related]
10. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
[TBL] [Abstract][Full Text] [Related]
11. MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
Sheng Y; Ng CP; Lourie R; Shah ET; He Y; Wong KY; Seim I; Oancea I; Morais C; Jeffery PL; Hooper J; Gobe GC; McGuckin MA
Int J Cancer; 2017 May; 140(10):2351-2363. PubMed ID: 28205224
[TBL] [Abstract][Full Text] [Related]
12. Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma.
Lee HW; Joo KM; Lim JE; Cho HJ; Cho HJ; Park MC; Seol HJ; Seo SI; Lee JI; Kim S; Jeong BC; Nam DH
Mol Cancer Res; 2013 Nov; 11(11):1375-86. PubMed ID: 23982215
[TBL] [Abstract][Full Text] [Related]
13. Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
Tei H; Miyake H; Fujisawa M
Hum Cell; 2015 Jul; 28(3):114-21. PubMed ID: 25862630
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
[TBL] [Abstract][Full Text] [Related]
15. SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.
Li XL; Chen XQ; Zhang MN; Chen N; Nie L; Xu M; Gong J; Shen PF; Su ZZ; Weng X; Tan JY; Zhao T; Zeng H; Zhou Q
Int J Clin Exp Pathol; 2015; 8(4):3871-81. PubMed ID: 26097571
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
17. Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
Gill DM; Agarwal N; Vaishampayan U
Am Soc Clin Oncol Educ Book; 2017; 37():319-329. PubMed ID: 28561652
[TBL] [Abstract][Full Text] [Related]
18. Proliferative role of BDNF/TrkB signaling is associated with anoikis resistance in cervical cancer.
Yuan Y; Ye HQ; Ren QC
Oncol Rep; 2018 Aug; 40(2):621-634. PubMed ID: 29989647
[TBL] [Abstract][Full Text] [Related]
19. Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates anoikis.
Yu M; Lu B; Liu Y; Me Y; Wang L; Li H
Mol Med Rep; 2017 Mar; 15(3):1103-1108. PubMed ID: 28112366
[TBL] [Abstract][Full Text] [Related]
20. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer.
Kim MS; Lee WS; Jeong J; Kim SJ; Jin W
Oncotarget; 2015 Nov; 6(37):40158-71. PubMed ID: 26515594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
